InVivo Therapeutics

$0.5948
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0093 (-1.57%) Today

+$0.0118 (+2.02%) As of 5:39 PM EST after-hours

Why Robinhood?

You can buy or sell NVIV and other stocks, options, and ETFs commission-free!

About NVIV

Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. Its clinical development program is the Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company was founded by Joseph P. Vacanti, Frank M. Reynolds, and Robert Langer in January 2005 and is headquartered in Cambridge, MA. The listed name for NVIV is InVivo Therapeutics Holdings Corp Common Stock.

CEO

Richard Toselli

Employees

Headquarters

Cambridge, Massachusetts

Founded

2005

Market Cap

12.34M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

1.32M

High Today

$0.6001

Low Today

$0.578

Open Price

$0.5923

Volume

1.47M

52 Week High

$11.99

52 Week Low

$0.4975

Collections

NVIV Earnings

-$0.49

-$0.33

-$0.16

$0.00

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Estimated

— per share

Actual

Expected Nov 9, After Hours